Somatic ERBB3-mutations have low incidence (typically <1%) across solid cancer types such as NSCLC and the oncogenic effect of ERBB3 depends on dimerization with other ERBB-family members because of its very weak intrinsic TK activity. The gene discussed is TKT; the disease is non-small cell lung carcinoma.